196 related articles for article (PubMed ID: 16210091)
1. Epigenetic immunomodulation of hematopoietic malignancies.
Gattei V; Fonsatti E; Sigalotti L; Degan M; Di Giacomo AM; Altomonte M; Calabrò L; Maio M
Semin Oncol; 2005 Oct; 32(5):503-10. PubMed ID: 16210091
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy.
Sigalotti L; Coral S; Fratta E; Lamaj E; Danielli R; Di Giacomo AM; Altomonte M; Maio M
Semin Oncol; 2005 Oct; 32(5):473-8. PubMed ID: 16210088
[TBL] [Abstract][Full Text] [Related]
3. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies.
Ying J; Gao Z; Li H; Srivastava G; Murray PG; Goh HK; Lim CY; Wang Y; Marafioti T; Mason DY; Ambinder RF; Chan AT; Tao Q
Br J Haematol; 2007 Mar; 136(6):829-32. PubMed ID: 17341268
[TBL] [Abstract][Full Text] [Related]
4. Role of epigenetic changes in hematological malignancies.
Lehmann U; Brakensiek K; Kreipe H
Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic targets for immune intervention in human malignancies.
Maio M; Coral S; Fratta E; Altomonte M; Sigalotti L
Oncogene; 2003 Sep; 22(42):6484-8. PubMed ID: 14528272
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
7. The fundamental role of epigenetics in hematopoietic malignancies.
Galm O; Herman JG; Baylin SB
Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
[TBL] [Abstract][Full Text] [Related]
8. Cancer-testis antigens in haematological malignancies.
Meklat F; Li Z; Wang Z; Zhang Y; Zhang J; Jewell A; Lim SH
Br J Haematol; 2007 Mar; 136(6):769-76. PubMed ID: 17223912
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies.
Fonsatti E; Altomonte M; Coral S; De Nardo C; Lamaj E; Sigalotti L; Natali PG; Maio M
Clin Ter; 2000; 151(3):187-93. PubMed ID: 10958054
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies.
Fraga MF; Berdasco M; Ballestar E; Ropero S; Lopez-Nieva P; Lopez-Serra L; Martín-Subero JI; Calasanz MJ; Lopez de Silanes I; Setien F; Casado S; Fernandez AF; Siebert R; Stifani S; Esteller M
Cancer Res; 2008 Jun; 68(11):4116-22. PubMed ID: 18519670
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells.
Ikeda JI; Morii E; Kimura H; Tomita Y; Takakuwa T; Hasegawa JI; Kim YK; Miyoshi Y; Noguchi S; Nishida T; Aozasa K
J Pathol; 2006 Sep; 210(1):75-84. PubMed ID: 16823897
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies.
Taniguchi H; Fernández AF; Setién F; Ropero S; Ballestar E; Villanueva A; Yamamoto H; Imai K; Shinomura Y; Esteller M
Cancer Res; 2009 Nov; 69(21):8447-54. PubMed ID: 19861541
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic changes in solid and hematopoietic tumors.
Toyota M; Issa JP
Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
17. Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.
Calabrò L; Fonsatti E; Altomonte M; Pezzani L; Colizzi F; Nanni P; Gattei V; Sigalotti L; Maio M
J Cell Physiol; 2005 Feb; 202(2):474-7. PubMed ID: 15389591
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Gene silencing by DNA methylation in haematological malignancies.
Boultwood J; Wainscoat JS
Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of apoptosis genes in hematopoietic malignancies.
Kitada S; Pedersen IM; Schimmer AD; Reed JC
Oncogene; 2002 May; 21(21):3459-74. PubMed ID: 12032782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
